Market revenue in 2020 | USD 43,917.2 million |
Market revenue in 2028 | USD 150,121.0 million |
Growth rate | 16.6% (CAGR from 2020 to 2028) |
Largest segment | (crispr)/cas9 |
Fastest growing segment | Meganuclease |
Historical data | 2017 - 2019 |
Base year | 2020 |
Forecast period | 2021 - 2028 |
Quantitative units | Revenue in USD million |
Market segmentation | (CRISPR)/Cas9, TALENs/MegaTALs, ZFN, Meganuclease |
Key market players worldwide | Thermo Fisher Scientific Inc, Takara Bio Inc, Danaher Corp, Promega, GenScript ProBio, New England Biolabs, Applied Materials Inc, Bio-Rad Laboratories Inc, Lucigen, Synthego, Addgene, Abcam PLC |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to mutation detection kits in genome editing market will help companies and investors design strategic landscapes.
(crispr)/cas9 was the largest segment with a revenue share of 43% in 2020. Horizon Databook has segmented the U.S. mutation detection kits in genome editing market based on (crispr)/cas9, talens/megatals, zfn, meganuclease covering the revenue growth of each sub-segment from 2017 to 2028.
The U.S. dominated North America’s market due to its extensive research activities in genomics, oncology, and whole-genome sequencing. Other factors, such as sophisticated research & medical infrastructure, funding, skilled personnel, and companies pushing for better research methods to identify innovative technologies for diagnosis & therapies, can be attributed to the significant adoption of mutation detection kits in genome editing market in this country.
The large revenue share of the U.S. can also be attributed to the local presence of market leaders, such as Thermo Fisher Scientific, Lucigen Corporation, GeneScript, and Integrated DNA Technologies, Inc., which are involved in the development and supply of mutation detection kits.
The regulatory paradigm followed for gene editing in the U.S. is distributed along the coordinated framework of Department of Agriculture (USDA), Environmental Protection Agency (EPA), and the U.S. Food and Drug Administration (FDA), rather than on biosafety law. This framework is significantly product-based, and the process comes into picture for regulatory assessment.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. mutation detection kits in genome editing market , including forecasts for subscribers. This country databook contains high-level insights into U.S. mutation detection kits in genome editing market from 2017 to 2028, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account